# Combination antiretroviral therapy: Evolution

Source page: https://www.materialinsights.org/technologies/antiretroviral_therapy/tech-evolution/

#### Timeline

The milestones from first idea to today

| Year | Milestone |
|---|---|
| 1983 | The Institut Pasteur team publishes the first description of HIV ^[3] |
| 1987 | AZT becomes the first FDA-approved drug for AIDS ^[1] |
| 1995 | Saquinavir becomes the first approved protease inhibitor; the ACTG 175 trial shows two drugs beat one ^[1] |
| 1996 | Triple-drug therapy is found to suppress HIV durably ^[1] |
| 2007 | Raltegravir, the first integrase inhibitor, is approved ^[1] |
| 2013 | Dolutegravir, a second-generation integrase inhibitor, is approved ^[1] |
| 2025 | 32.1 million people are on treatment worldwide ^[2] |

as of 2026-11-11

#### Performance then and now

How much better it has become on the measures that matter

| Metric | Unit | Then | Year (then) | Now | Year (now) |
|---|---|---|---|---|---|
| price of a year's antiretroviral treatment per person in poorer countries | USD per person per year | 10,000 | 2000 | 100 | 2016 |

as of 2026-11-11. 2000: a basic regimen cost over $10,000 per person per year; 2016: the lowest generic price of a WHO-recommended first-line regimen was $100 [5]; the two prices are for different regimens and the source does not say whether dollars are nominal or real.

#### Lineage

The technologies it came from and the ones that came from it
 Came before it

- [Asa Synthetic drugs (medicinal chemistry)](https://www.materialinsights.org/technologies/synthetic_drugs/) Antiretrovirals are small-molecule drugs designed by chemists, the tradition of synthetic medicines.
 Works with

- [Syr Hypodermic syringe](https://www.materialinsights.org/technologies/hypodermic_syringe/) Long-acting injectable treatment, studied in trials presented in 2024, is an alternative to daily pills ^[1].
- [PCR Polymerase chain reaction](https://www.materialinsights.org/technologies/polymerase_chain_reaction/) PCR-based tests detect HIV and measure the amount of virus in the blood, which shows whether treatment is working.

as of 2026-11-11

#### Sources

1. [Antiretroviral Drug Discovery and Development](https://www.niaid.nih.gov/diseases-conditions/antiretroviral-drug-development) National Institute of Allergy and Infectious Diseases (NIH)
2. [Fact sheet 2026](https://www.unaids.org/sites/default/files/2026-07/2026_UNAIDS_Global_HIV_Factsheet_en.pdf) UNAIDS, 2026
3. [Nobel Prize in Medicine 2008 awarded to Professors Françoise Barré-Sinoussi and Luc Montagnier](https://www.pasteur.fr/en/whats-new/press-area/press-releases-and-press-kits/nobel-prize-medicine-2008-awarded-professors-francoise-barre-sinoussi-and-luc-montagnier) Institut Pasteur, 2008

## Other sections

- [Summary](https://www.materialinsights.org/technologies/antiretroviral_therapy/index.md)
- [Overview](https://www.materialinsights.org/technologies/antiretroviral_therapy/tech-overview/index.md)
- [Science](https://www.materialinsights.org/technologies/antiretroviral_therapy/tech-science/index.md)
- [Materials](https://www.materialinsights.org/technologies/antiretroviral_therapy/tech-materials/index.md)
- [Energy footprint](https://www.materialinsights.org/technologies/antiretroviral_therapy/tech-energy-footprint/index.md)
- [Industries](https://www.materialinsights.org/technologies/antiretroviral_therapy/tech-industries/index.md)
